Molecular regulation of angiogenesis and lymphangiogenesis, Nature Reviews Molecular Cell Biology, vol.17, issue.6, pp.464-78, 2007. ,
DOI : 10.1016/S0002-9440(10)63851-5
Matrix Metalloproteinase-9 Is Required for Tumor Vasculogenesis but Not for Angiogenesis: Role of Bone Marrow-Derived Myelomonocytic Cells, Cancer Cell, vol.13, issue.3, 2008. ,
DOI : 10.1016/j.ccr.2007.11.032
Lymphangiogenesis in development and human disease, Nature, vol.36, issue.7070, pp.946-53, 2005. ,
DOI : 10.1038/ng1383
Arterial and Venous Thrombotic Complications with Thalidomide in Multiple Myeloma, Archives of Medical Research, vol.39, issue.2, pp.257-265, 2008. ,
DOI : 10.1016/j.arcmed.2007.08.005
Molecular mechanisms of tumor vascularization, Critical Reviews in Oncology/Hematology, vol.54, issue.1, pp.53-61, 2005. ,
DOI : 10.1016/j.critrevonc.2004.11.006
The evolution of thalidomide and its IMiD derivatives as anticancer agents, Nature Reviews Cancer, vol.18, issue.4, pp.314-336, 2004. ,
DOI : 10.1016/S0167-5699(97)01118-3
Cell???matrix adhesion, Journal of Cellular Physiology, vol.114, issue.3, pp.565-73, 2007. ,
DOI : 10.1016/j.bbamcr.2004.04.007
Le rôle du facteur plaquettaire 4 dans la régulation et l'inhibition de l'angiogenèse. Hématologie. 2004 sept-oct, pp.365-374 ,
Signaling and Functions of Angiopoietin-1 in Vascular Protection, Circulation Research, vol.98, issue.8, pp.1014-1037, 2006. ,
DOI : 10.1161/01.RES.0000218275.54089.12
Tumor angiogenesis???new drugs on the block, Nature Biotechnology, vol.394, issue.10, pp.963-971, 1999. ,
DOI : 10.1038/28412
Comparative Evaluation of FGF-2-, VEGF-A-, and VEGF-C-Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability, Circulation Research, vol.94, issue.5, pp.664-70, 2004. ,
DOI : 10.1161/01.RES.0000118600.91698.BB
Angiogenesis in health and disease, Nature Medicine, vol.5, issue.suppl. 1, pp.653-60, 2003. ,
DOI : 10.1006/mthe.2002.0590
Les m??talloprot??ases matricielles et leurs inhibiteurs synth??tiques dans la progression tumorale, m??decine/sciences, vol.18, issue.5, pp.565-75, 2002. ,
DOI : 10.1051/medsci/2002185565
URL : http://www.medecinesciences.org/articles/medsci/pdf/2002/05/medsci2002185p565.pdf
Oxygen sensing by HIF hydroxylases, Nature Reviews Molecular Cell Biology, vol.5, pp.343-354, 2004. ,
Endothelial signaling during development, Nature Medicine, vol.2, issue.6, pp.661-669, 2003. ,
DOI : 10.1517/14712598.2.8.805
Hypoxia-inducible factor 1: regulation, involvement in carcinogenesis and target for anticancer therapy, Bull Cancer. Feb, vol.92, issue.2, pp.119-146, 2005. ,
URL : https://hal.archives-ouvertes.fr/hal-00077264
Les mécanismes de l'angiogenèse. Applications médicales et thérapeutiques. Rev Méd Interne, pp.1064-82, 2001. ,
Tissue factor: a mini-review, Journal of Tissue Engineering and Regenerative Medicine, vol.267, issue.3, pp.161-170, 2007. ,
DOI : 10.1042/bj3100605
Angiogenesis and anti-angiogenic strategies for glioblastoma. Bull Cancer, pp.360-72, 2005. ,
Une nouvelle interface dans l'hémostase et la réaction inflammatoire, pp.825-856, 1921. ,
Antineoplastic treatment and venous thrombosis. Bull Cancer, Feb, vol.193, issue.2, pp.171-179, 2006. ,
Risque thromboembolique des th??rapeutiques antiangiog??niques utilis??es dans les cancers, Pathologie Biologie, vol.56, issue.4, pp.195-204, 2008. ,
DOI : 10.1016/j.patbio.2008.02.013
HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion.Cancer Cell, pp.206-226, 2008. ,
Proteases ??? invasion and more, Nature, vol.394, issue.6693, pp.527-535, 1998. ,
DOI : 10.1083/jcb.139.7.1861
Angiogenesis in cancer: molecular mechanisms, clinical impact. Langenbecks Arch Surg, pp.371-380, 2007. ,
Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling, Experimental Cell Research, vol.312, issue.5, pp.630-671, 2006. ,
DOI : 10.1016/j.yexcr.2005.09.002
Le ciblage de l???angiogen??se en oncologie, Pathologie Biologie, vol.54, issue.4, pp.199-205, 2006. ,
DOI : 10.1016/j.patbio.2004.11.003
Angiogenesis as a therapeutic target, Nature, vol.65, issue.7070, pp.967-74, 2005. ,
DOI : 10.1158/0008-5472.CAN-05-0626
Mechanisms of adaptive angiogenesis to tissue hypoxia, Angiogenesis, vol.336, issue.1, pp.121-161, 2008. ,
DOI : 10.4161/cc.6.5.3922
Plaquettes et tumeurs, Hématologie, vol.12, issue.6, pp.400-411, 2006. ,
Differential function of Tie2 at cell???cell contacts and cell???substratum contacts regulated by angiopoietin-1, Nature Cell Biology, vol.9, issue.5, pp.513-539, 2008. ,
DOI : 10.1091/mbc.E05-07-0647
Tumor microvasculature and microenvironment: targets for antiangiogenesis and normalization. Microvasc Res, pp.72-84, 2007. ,
M??talloprot??inases et angiogen??se, Pathologie Biologie, vol.51, issue.3, pp.161-167, 2003. ,
DOI : 10.1016/S0369-8114(03)00018-X
Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma, Haematologica, vol.89, issue.9, pp.1141-1143, 2004. ,
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions, Journal of Clinical Oncology, vol.23, issue.6, pp.1295-311, 2005. ,
DOI : 10.1200/JCO.2005.10.022
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia, The Journal of Cell Biology, vol.15, issue.6, pp.1163-77, 2003. ,
DOI : 10.1002/(SICI)1521-1878(200003)22:3<219::AID-BIES3>3.0.CO;2-A
URL : http://jcb.rupress.org/content/jcb/161/6/1163.full.pdf
Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost, Review. Erratum Thromb Haemost, vol.99100, issue.61, pp.1001-7171, 2008. ,
Le système de l'hémostase dans la modulation de l'angiogenèse. Hématologie, pp.184-91, 2001. ,
The VEGF family, the inside story. Cell, pp.591-593, 2007. ,
Roles of PDGF in animal development. Development, 2003. ,
Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2, Proceedings of the National Academy of Sciences, vol.62, issue.21, pp.8904-8913, 2003. ,
DOI : 10.1023/A:1012201300188
Expression and regulation of murine macrophage angiopoietin-2, Cellular Immunology, vol.234, issue.2, pp.102-111, 2005. ,
DOI : 10.1016/j.cellimm.2005.06.001
A reevaluation of integrins as regulators of angiogenesis, Nature Medicine, vol.4, issue.9, pp.918-939, 2002. ,
DOI : 10.1038/nm0302-193
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor, The FASEB Journal, vol.17, issue.12, pp.1609-1630, 2003. ,
DOI : 10.1016/S0092-8674(00)81812-7
Angiogenesis inhibitor therapies: focus on hypertension and kidney toxicity]. Bull Cancer, pp.981-987, 2007. ,
DOI : 10.1053/j.ajkd.2007.04.025
Molecular regulation of vessel maturation, Nature Medicine, vol.4, issue.6, pp.685-93, 2003. ,
DOI : 10.3109/10739689709146803
Angiogenesis: Basement membranes: structure, assembly and role in tumour angiogenesis, Nature Reviews Cancer, vol.3, issue.6, pp.422-455, 2003. ,
DOI : 10.1038/nrc1094
Mechanisms of adverse effects of anti-VEGF therapy for cancer, British Journal of Cancer, vol.280, issue.12, pp.1788-95, 2007. ,
DOI : 10.1038/nm1428
Vascular Endothelial Growth Factor and Its Receptor as Drug Targets in Hematological Malignancies, Current Drug Targets, vol.8, issue.2, pp.257-68, 2007. ,
DOI : 10.2174/138945007779940089
Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer, pp.387-92, 2007. ,
Drug Insight: thalidomide as a treatment for multiple myeloma, Nature Clinical Practice Oncology, vol.104, issue.5, pp.262-70, 2005. ,
DOI : 10.1038/sj.thj.6200401
Thalidomid: current role in the treatment of non-plasma cell malignancies, J Clin Oncol Review. Erratum J Clin Oncol, vol.2222, issue.1214, pp.2477-882973, 2004. ,
Effet anti-angiogénique de l'imatinib mésylate (Glivec®) dans les leucémies myéloïdes chroniques. Hématologie. 2004 nov-dec, pp.464-471 ,
The role of PDGF in radiation oncology, Radiation Oncology, vol.2, issue.1, p.5, 2007. ,
DOI : 10.1186/1748-717X-2-5
Hypoxia: A key regulator of angiogenesis in cancer, Cancer and Metastasis Reviews, vol.112, issue.Suppl 4, pp.281-90, 2007. ,
DOI : 10.7326/0003-4819-138-8-200304150-00014
Angiogenesis: regulators and clinical applications, Biochemical Pharmacology, vol.61, issue.3, pp.253-70, 2001. ,
DOI : 10.1016/S0006-2952(00)00529-3
Expression of VEGF-C and its receptor VEGFR-3 in the bone marrow of patients with acute myeloid leukaemia, Leukemia Research, vol.32, issue.6, pp.954-61, 2008. ,
DOI : 10.1016/j.leukres.2007.10.005
Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies, Leukemia, vol.8, issue.8, 2006. ,
DOI : 10.1097/00130404-200201000-00003
Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status, Leukemia, vol.7, issue.6, pp.1312-1317, 2007. ,
DOI : 10.1016/S1525-1578(10)60589-2
Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin, Thrombosis Research, vol.121, issue.5, pp.637-682, 2008. ,
DOI : 10.1016/j.thromres.2007.06.015
The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer, Anti-Cancer Drugs, vol.12, issue.5, pp.387-400, 2001. ,
DOI : 10.1097/00001813-200106000-00001
Thromboembolic events with lenalidomide-based therapy for multiple myeloma. Cancer, pp.1522-1530, 2008. ,
Microparticles are vectors of paradoxical information in vascular cells including the endothelium: role in health and diseases. Pharmacol Rep, pp.75-84, 2008. ,
Platelet-Derived Growth Factor???BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells, Trends in Cardiovascular Medicine, vol.16, issue.1, pp.25-33, 2006. ,
DOI : 10.1016/j.tcm.2005.11.003
Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development, The FASEB Journal, vol.18, issue.13, pp.1507-1522, 2004. ,
DOI : 10.1002/aja.1002030109
2.5???kDa and 5.0???kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis, International Journal of Experimental Pathology, vol.53, issue.1, 2000. ,
DOI : 10.1038/10518
URL : https://hal.archives-ouvertes.fr/hal-00600868
Low-molecular-weight heparins and angiogenesis., APMIS, vol.155, issue.9, pp.79-102, 2006. ,
DOI : 10.1074/jbc.M303569200
Tumor microenvironment and angiogenesis, Frontiers in Bioscience, vol.Volume, issue.13, pp.6537-53, 2008. ,
DOI : 10.2741/3173
Endogenous inhibitors of angiogenesis.Cancer Res, May, vol.1565, issue.10, pp.3967-79, 2005. ,
Maladie veineuse thromboembolique et??cancer, La Revue de M??decine Interne, vol.27, issue.4, pp.313-335, 2006. ,
DOI : 10.1016/j.revmed.2005.11.016
Angiogen??se et morphogen??se de l'arbre vasculaire : de la biologie cellulaire ?? la clinique., m??decine/sciences, vol.16, issue.12, pp.1378-86, 2000. ,
DOI : 10.4267/10608/1593
Mechanisms of Disease: the impact of antithrombotic therapy in cancer patients, Nature Clinical Practice Oncology, vol.2, issue.7, pp.356-63, 2005. ,
DOI : 10.1038/ncponc0225
Signaling via Vascular Endothelial Growth Factor Receptors, Experimental Cell Research, vol.253, issue.1, pp.117-147, 1999. ,
DOI : 10.1006/excr.1999.4707
Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting, PLoS Medicine, vol.11, issue.1, p.19, 2008. ,
DOI : 10.1371/journal.pmed.0050019.st002
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications, Blood, vol.105, issue.4, pp.1383-95, 2005. ,
DOI : 10.1182/blood-2004-07-2909
Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature, vol.9, issue.suppl. 5, pp.437-480, 2006. ,
DOI : 10.1016/j.devcel.2005.09.010
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis, Cytokine & Growth Factor Reviews, vol.16, issue.2, pp.159-78, 2005. ,
DOI : 10.1016/j.cytogfr.2005.01.004
Regulation of Vasculogenesis by Platelet-Mediated Recruitment of Bone Marrow-Derived Cells, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.28, issue.2, pp.217-239, 2008. ,
DOI : 10.1161/ATVBAHA.107.151159
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer, pp.826-861, 2002. ,
Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells, Blood, vol.104, issue.7, pp.2084-2090, 2004. ,
DOI : 10.1182/blood-2004-01-0336
Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr Lek, pp.135-143, 2006. ,
Tissue Factor in Cancer and Angiogenesis: The Molecular Link between Genetic Tumor Progression, Tumor Neovascularization, and Cancer Coagulopathy, Seminars in Thrombosis and Hemostasis, vol.32, issue.01, pp.54-70, 2006. ,
DOI : 10.1055/s-2006-933341
Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth, Journal of Investigative Dermatology Symposium Proceedings, vol.5, issue.1, pp.24-33, 2000. ,
DOI : 10.1046/j.1087-0024.2000.00012.x
URL : https://doi.org/10.1046/j.1087-0024.2000.00012.x
Regulation of tumor angiogenesis by thrombospondin-1, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1765, issue.2, pp.178-88, 2006. ,
DOI : 10.1016/j.bbcan.2005.11.002
Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma, Oncogene, vol.25, issue.31, pp.4257-66, 2006. ,
DOI : 10.1038/sj.onc.1209456
Thalidomide for Patients With Relapsed Multiple Myeloma After High-Dose Chemotherapy and Stem Cell Transplantation: Results of an Open-Label Multicenter Phase 2 Study of Efficacy, Toxicity, and Biological Activity, Mayo Clinic Proceedings, vol.79, issue.7, pp.875-82, 2004. ,
DOI : 10.4065/79.7.875
Tissue Factor, Thrombin, and Cancer, Chest, vol.124, issue.3, pp.58-68, 2003. ,
DOI : 10.1378/chest.124.3_suppl.58S
Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial, Cancer Chemotherapy and Pharmacology, vol.25, issue.suppl 1, pp.227-260, 2008. ,
DOI : 10.1007/s00280-007-0596-3
Regulation of vascular morphogenesis by Notch signaling. Genes Dev, Oct, vol.1521, issue.20, pp.2511-2535, 2007. ,
Leukocytes, inflammation, and angiogenesis in cancer: fatal attractions, Journal of Leukocyte Biology, vol.35, issue.4, pp.682-686, 2006. ,
DOI : 10.1080/07853890310017053
Redundant signaling of tissue factor and thrombin in cancer progression?, Journal of Thrombosis and Haemostasis, vol.63, issue.8, pp.1584-1591, 2007. ,
DOI : 10.1038/nm1037
Matrix metalloproteinases and angiogenesis, Journal of Cellular and Molecular Medicine, vol.9, issue.2, pp.267-85, 2005. ,
DOI : 10.1073/pnas.220399597
Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell???cell and cell???matrix contacts, Nature Cell Biology, vol.19, issue.5, pp.527-564, 2008. ,
DOI : 10.1074/jbc.M500292200
Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park), pp.1346-52, 1367. ,
Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia, Haematologica, vol.91, issue.9, pp.1203-1214, 2006. ,
Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia, Leukemia, vol.93, issue.9, pp.1901-1907, 2007. ,
DOI : 10.1016/j.ccr.2004.09.030
Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis, Angiogenesis, vol.79, issue.4, pp.225-255, 2006. ,
DOI : 10.4049/jimmunol.174.1.215
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis, BMB Reports, vol.41, issue.4, pp.278-86, 2008. ,
DOI : 10.5483/BMBRep.2008.41.4.278
Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis, Molecular Cancer Research, vol.5, issue.7, pp.655-65, 2007. ,
DOI : 10.1158/1541-7786.MCR-07-0072
Role of matrix proteolysis in angiogenesis, Journ Annu Diabetol Hotel Dieu, pp.23-32, 2002. ,
Molecular pathways of angiogenesis inhibition, Biochemical and Biophysical Research Communications, vol.355, issue.1, pp.1-5, 2007. ,
DOI : 10.1016/j.bbrc.2007.01.123
Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation, Nature, vol.196, issue.7204, pp.656-60, 2008. ,
DOI : 10.1161/01.RES.88.6.623
The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions, Clinical Science, vol.109, issue.3, pp.227-268, 2005. ,
DOI : 10.1042/CS20040370
Extracellular control of TGF?? signalling in vascular development and disease, Nature Reviews Molecular Cell Biology, vol.355, issue.11, pp.857-69, 2007. ,
DOI : 10.1161/01.HYP.28.5.881
Properties of thalidomide and its analogues: Implications for anticancer therapy, The AAPS Journal, vol.7, issue.1, pp.14-19, 2005. ,
DOI : 10.1208/aapsj070103
PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis, Blood, vol.104, issue.10, pp.3198-204, 2004. ,
DOI : 10.1182/blood-2004-04-1485
URL : http://www.bloodjournal.org/content/bloodjournal/104/10/3198.full.pdf
Bone marrow angiogenesis in multiple myeloma, Leukemia, vol.19, issue.2, pp.193-202, 2006. ,
DOI : 10.1038/sj.leu.2403776
Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma, Journal of Clinical Oncology, vol.23, issue.23, pp.5334-5380, 2005. ,
DOI : 10.1200/JCO.2005.03.723
Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis, Current Opinion in Hematology, vol.14, issue.5, pp.468-80, 2007. ,
DOI : 10.1097/MOH.0b013e3282a6457f
Mécanismes moléculaires de l'angiogénèse. Hématologie. 1997 may-jun, pp.221-230 ,
Inhibition of tissue factor signaling suppresses tumor growth, Blood, vol.111, issue.1, pp.190-199, 2008. ,
DOI : 10.1182/blood-2007-07-101048
Differential effect of the low-molecularweight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties Erratum in: Haematologica, Haematologica. Feb, vol.91, issue.2, pp.207-221, 2006. ,
Heparanase, heparin and the coagulation system in cancer progression, Thrombosis Research, vol.120, issue.2, pp.112-132, 2007. ,
DOI : 10.1016/S0049-3848(07)70139-1
Endostatin Signaling and Regulation of Endothelial Cell???Matrix Interactions, Adv Cancer Res, vol.94, pp.197-229, 2005. ,
DOI : 10.1016/S0065-230X(05)94005-0
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis, Blood, vol.105, issue.4, pp.1734-1775, 2005. ,
DOI : 10.1182/blood-2004-05-2042
Thrombospondin-based antiangiogenic therapy, Microvascular Research, vol.74, issue.2-3, pp.90-99, 2007. ,
DOI : 10.1016/j.mvr.2007.04.007
URL : http://europepmc.org/articles/pmc4696437?pdf=render